WondfoCartis is the wholly - owned subsidiary of the HK-based joint venture, which is funded by Guangzhou Wondfo Biotech Co., Ltd., a globally recognized fast growing POCT leader in China, and Biocartis Group NV, a leading Belgium biotechnology company in Europe.
The two sides jointly promote the introduction and commercial application of a fully automatic molecular diagnostic platform - Idylla™ （Mainland China trademark, easegene™）in cancer precision treatment in Mainland China. We are committed to providing accurate, sensitive and fast diagnosis for medicine guidance.
WondfoCartis is the pioneer in introducing the concept of fully automatic MDx in cancer precision treatment in China. easegene™, a fully automated, sample-to-result PCR-based molecular diagnostic system, provides same-day results. It takes less than 2 minutes’ hands-on-time and brings out the accurate and reliable result within around 2 hours.Based on its outstanding ease-of-use and pollution-proof design, easegene™ is a convenient device for the end-users and brings more benefit to patients. As easegene™ can be used with multiple biological sample types, it can be applied to detection various targets and provide reliable results. Reagents can remain stable for a long time at room temperature, extending the application range of easegene™.
Since Idylla™ was launched, Biocartis has sold 15 companion diagnostics products guiding the treatment of lung cancer, colorectal cancer, melanoma and etc. in more than 70 countries and regions. The detection panels with clinical significance include EGFR, NRAS, KRAS, BRAF and etc. It also covers various sample types including solid and liquid biopsies.
"Do Not Let Life Wait" is our core value of service. WondfoCartis will strive to make further improvement and development of new products and extensively cooperate with pharmaceutical factories in Companion Diagnostics research in order to meet the specific needs of the Chinese market, improve diagnostics services and boost the medical science in China.